Ashford Capital Management Inc. Has $4.05 Million Holdings in Intuitive Surgical, Inc. $ISRG

Ashford Capital Management Inc. boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 69.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 7,143 shares of the medical equipment provider’s stock after buying an additional 2,920 shares during the period. Ashford Capital Management Inc.’s holdings in Intuitive Surgical were worth $4,046,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of ISRG. Brighton Jones LLC boosted its stake in Intuitive Surgical by 24.9% in the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after buying an additional 731 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in Intuitive Surgical by 3.8% in the second quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock worth $504,000 after purchasing an additional 34 shares in the last quarter. Schnieders Capital Management LLC. boosted its stake in Intuitive Surgical by 38.0% in the second quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock worth $529,000 after purchasing an additional 268 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in Intuitive Surgical in the second quarter worth $200,000. Finally, Main Street Financial Solutions LLC boosted its stake in Intuitive Surgical by 92.4% in the second quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock worth $1,592,000 after purchasing an additional 1,407 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Activity

In other news, Director Amy L. Ladd sold 500 shares of Intuitive Surgical stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $473.46, for a total transaction of $236,730.00. Following the transaction, the director owned 239 shares in the company, valued at $113,156.94. The trade was a 67.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Iman Jeddi sold 5,625 shares of Intuitive Surgical stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the transaction, the senior vice president owned 6,463 shares in the company, valued at $2,718,014.65. This trade represents a 46.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 7,169 shares of company stock worth $3,059,135 in the last 90 days. Corporate insiders own 0.60% of the company’s stock.

Intuitive Surgical Stock Up 0.1%

Shares of ISRG opened at $417.07 on Wednesday. Intuitive Surgical, Inc. has a 12-month low of $396.68 and a 12-month high of $603.88. The firm has a market capitalization of $147.71 billion, a PE ratio of 50.55, a price-to-earnings-growth ratio of 3.39 and a beta of 1.46. The stock’s fifty day simple moving average is $441.47 and its 200-day simple moving average is $493.43.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, beating analysts’ consensus estimates of $2.08 by $0.42. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.62 billion. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The firm’s revenue was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.81 earnings per share. Analysts anticipate that Intuitive Surgical, Inc. will post 8.57 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on ISRG. Barclays set a $651.00 price objective on Intuitive Surgical and gave the stock an “overweight” rating in a research note on Thursday, April 23rd. HSBC reduced their price objective on Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. TD Cowen reduced their price objective on Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Evercore reduced their price objective on Intuitive Surgical from $550.00 to $480.00 and set a “neutral” rating on the stock in a research note on Monday, April 6th. Finally, Jefferies Financial Group reduced their price objective on Intuitive Surgical from $560.00 to $515.00 and set a “hold” rating on the stock in a research note on Wednesday, April 22nd. Nineteen equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $573.42.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.